4-(氯甲基)-1,3-噻唑-2-甲酰氯 | 200418-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(氯甲基)-1,3-噻唑-2-甲酰氯
• 英文名称: 4-Chloromethyl-thiazole-2-carbonyl chloride
• 英文别名: 4-(chloromethyl)-1,3-thiazole-2-carbonyl Chloride
• CAS: 200418-16-2
• 化学式: C₅H₃Cl₂NOS
• 分子量: 196.057
• InChiKey: YYRHYWJJIKIDHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(氯甲基)-1,3-噻唑-2-甲酰氯 在 N,N-二甲基丙烯基脲 、 三氯化铝 、 sodium bromide 作用下， 反应 6.75h， 生成 6-(4-Fluoro-phenyl)-3-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-thiazole-2-carbonyl]-indole-1-carboxylic acid dimethylamide
  参考文献：
  名称：

  Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists

  摘要：

  Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure-activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N,N-dimethylcarbamoyl)-4-ethynyl-3-(3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl] benzoyl}indole hydrochloride (ABT-491, 22m.HCl) which has been evaluated extensively and is currently in clinical development.

  DOI：

  10.1021/jm970389+
• 作为产物：
  描述：

  4-(氯甲基)-1,3-噻唑-2-羧酸乙酯 在 氢氧化钾 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 生成 4-(氯甲基)-1,3-噻唑-2-甲酰氯
  参考文献：
  名称：

  Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists

  摘要：

  Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal models. The compounds arose from the combination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) with the methylimidazopyridine heterocycle moiety of British Biotechnology's BB-882 (1) and possess the positive attributes of both of these clinical candidates. Structure-activity relationship (SAR) studies indicated that modification of the indole and benzoyl spacer of lead compound 7b gave analogues that were more potent, longer-lived, and bioavailable and resulted in the identification of 1-(N,N-dimethylcarbamoyl)-4-ethynyl-3-(3-fluoro-4-[(1H-2-methylimidazo[4,5-c]pyrid-1-yl)methyl] benzoyl}indole hydrochloride (ABT-491, 22m.HCl) which has been evaluated extensively and is currently in clinical development.

  DOI：

  10.1021/jm970389+

文献信息

• [EN] BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES<br/>[FR] DÉRIVÉS DE BENZPYRAZOLE EN TANT QU'INHIBITEURS DE P13 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2009147188A1

  公开（公告）日：2009-12-10

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  这项发明涉及某些新颖化合物。具体来说，该发明涉及式(I)的化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• [EN] 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES<br/>[FR] DÉRIVÉS DE 4-CARBOXAMIDE INDAZOLE UTILES EN TANT QU'INHIBITEURS DE P13 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2009147187A1

  公开（公告）日：2009-12-10

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  这项发明涉及某些新颖的化合物。具体来说，该发明涉及具有式(I)的化合物及其盐。该发明的化合物是P13-激酶活性的抑制剂。
• BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES
  申请人：Baldwin Ian Robert

  公开号：US20110178063A1

  公开（公告）日：2011-07-21

  The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

  该发明涉及公式（I）的某些新化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
• 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
  申请人：GlaxoGroupLimited

  公开号：US08163743B2

  公开（公告）日：2012-04-24

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  本发明涉及某些新型化合物。具体来说，本发明涉及公式（I）的化合物及其盐。本发明的化合物是P13-激酶活性的抑制剂。
• 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES
  申请人：Baldwin Ian Robert

  公开号：US20110112070A1

  公开（公告）日：2011-05-12

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  本发明涉及某些新颖化合物。具体而言，本发明涉及式(I)化合物及其盐。本发明的化合物是P13-激酶活性抑制剂。